论文部分内容阅读
目的:分析手术不可行的早期肝癌(HCC)患者接受经皮微波消融(PMVA)治疗后的长期疗效。方法:选取2007年1月至2010年1月105例手术不可行的早期肝癌患者经皮热消融治疗,观察肿瘤完全消融率、严重并发症发生率、总体生存率、无瘤生存率并分析预后相关影响因素。结果:肿瘤完全消融率95.7%,并发症发生率3.8%,1、3、5年总体生存率分别为97.1%、66.7%、46.7%,1、3、5年无瘤生存率分别为82.9%、48.6%、31.4%。年龄>65岁和肿瘤最大直径≥3 cm是影响术后无瘤生存率独立危险因素;年龄>65岁和肿瘤复发是总生存率的独立风险因素。结论 :对于手术不可行的早期HCC患者,PMWA是安全且疗效理想的治疗方法,可作为该类HCC患者的首选治疗。
Objective: To analyze the long-term efficacy of percutaneous microwave ablation (PMVA) in patients with early stage hepatocellular carcinoma (HCC) who are not feasible for surgery. METHODS: From January 2007 to January 2010, 105 patients with early-stage liver cancer who were not feasible for surgery were treated with thermal thermal ablation. The rate of complete ablation, serious complications, overall survival, tumor-free survival, and prognosis were observed. Relevant influencing factors. Results: The rate of complete tumor ablation was 95.7%, the incidence of complications was 3.8%, the overall survival rate was 97.1%, 66.7%, and 46.7% in 1, 3, and 5 years, and the disease-free survival rate was 82.9% in 1, 3, and 5 years, respectively. , 48.6%, 31.4%. Age >65 years and maximum tumor diameter ≥3 cm were independent risk factors affecting postoperative disease-free survival; age >65 years and tumor recurrence were independent risk factors for overall survival. Conclusion : PMWA is a safe and effective therapeutic method for early HCC patients who are not feasible for surgery. It can be used as the first choice for HCC patients.